Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
화요일, 9월 01

Regeneron Pharmaceuticals Inc

REGNNASDAQ
Trade with Public
Trade with Public
$815.88
16.792.1%
마지막 업데이트: Sep 1, 1:10 PM
개요뉴스실적 전망이벤트목표가재무심리지분 현황배당금비교옵션주식 보고서

Regeneron Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Regeneron Pharmaceuticals (REGN).

Price Target Range — 6 Quarters

Analyst Consensus — 23 Analysts

17Buy
6Hold
Consensus RatingBuy# Analysts23Avg. Consensus PT$797Upside to Avg. PT-2.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 17, 2026Leerink PartnersDavid RisingerPT RaiseMarket Perform$641→$824
Aug 3, 2026CitigroupGeoff MeachamPT RaiseNeutral$700→$740
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citigroup Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $740

Citigroup analyst Geoff Meacham maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and raises the price target from $700 to $740.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1030

Guggenheim analyst Brad Canino maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $1000 to $1030.
Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $737

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the price target from $696 to $737.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $758

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $730 to $758.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $795

Cantor Fitzgerald analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $750 to $795.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $750

Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $700 to $750.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved